Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood
Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood
复制标题
DOI：
10.1111/j.1365-2036.2011.04665.x
复制
发表时间：
2011-06-15
影响因子：
7.6
通讯作者：
Szajewska, H.
中科院分区：
文献类型：
--
作者：
Horvath, A.;Dziechciarz, P.;Szajewska, H.
目的系统评价鼠李糖乳杆菌GG（Lactobacillus rhamnosus GG，LGG）治疗小儿腹痛相关性功能性胃肠病的疗效。方法MEDLINE、EMBASE、CINAHL、科克伦图书馆、检索试验登记和主要会议记录，以寻找评价LGG补充剂治疗腹痛儿童的随机对照试验（RCT），基于罗马II或罗马III标准的相关功能性胃肠道疾病。偏倚的风险进行了评估的产生分配序列，分配隐藏，盲法和follow-up.ResultsCompared安慰剂，LGG补充剂与治疗应答率显着较高（定义为无疼痛或疼痛强度降低）（3项RCT，n = 290;风险比，RR 1.31，95%CI 1.08-1.59，需要治疗的人数，NNT 7，95%CI 4-22）和肠易激综合征（IBS）亚组（3项RCT，n = 167; RR 1.70，95% CI 1.27-2.27，NNT 4，95% CI 3-8）。然而，在接受安慰剂或LGG治疗的功能性腹痛或功能性消化不良儿童之间，没有发现治疗应答率的差异。在整个研究人群和IBS亚组中，疼痛强度显著降低。疼痛的频率显着降低在IBS subgroup only.ConclusionThe use of Lactobacillus rhamnosus GG moderately increases treatment success in children with abdominal pain related functional gastrointestinal disorders，especially among children with IBS.
P>BackgroundA lack of reliable treatments for abdominal pain-related functional gastrointestinal disorders prompts interest in new therapies.AimTo evaluate systematically the effect of Lactobacillus rhamnosus GG (LGG) for treating abdominal pain-related functional gastrointestinal disorders in children.MethodsMEDLINE, EMBASE, CINAHL, the Cochrane Library, trial registries and proceedings of major meetings were searched for randomised controlled trials (RCTs) evaluating LGG supplementation in children with abdominal pain-related functional gastrointestinal disorders based on the Rome II or Rome III criteria. Risk of bias was assessed for generation of the allocation sequence, allocation concealment, blinding and follow-up.ResultsCompared with placebo, LGG supplementation was associated with a significantly higher rate of treatment responders (defined as no pain or a decrease in pain intensity) in the overall population with abdominal pain-related functional gastrointestinal disorders (three RCTs, n = 290; risk ratio, RR 1.31, 95% CI 1.08-1.59, number needed to treat, NNT 7, 95% CI 4-22) and in the irritable bowel syndrome (IBS) subgroup (three RCTs, n = 167; RR 1.70, 95% CI 1.27-2.27, NNT 4, 95% CI 3-8). However, no difference was found in the rate of treatment responders between children with functional abdominal pain or functional dyspepsia who received placebo or LGG. The intensity of pain was significantly reduced in the overall study population and in the IBS subgroup. The frequency of pain was significantly reduced in the IBS subgroup only.ConclusionThe use of Lactobacillus rhamnosus GG moderately increases treatment success in children with abdominal pain-related functional gastrointestinal disorders, particularly among children with IBS.